Aims Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT 1B/1D receptor agonist developed for the acute oral treatment of migraine. A highly sensitive LCMS-MS assay has been developed which allows quantification of plasma concentrations of zolmitriptan and its active metabolite, 183C91, after therapeutic doses. Two studies using this assay method were conducted to investigate the pharmacokinetics, including absolute bioavailability, of 2.5 and 5 mg oral doses of zolmitriptan in men and women, the dose-proportionality of 2.5, 5 and 10 mg doses and the effect of food on the pharmacokinetics of a 5 mg oral dose. Methods Two randomized, balanced, open-label, 4-period crossover studies were conducted in a total of 32 healthy volunteers. The first study determined the absolute bioavailability of 2.5 and 5 mg doses of zolmitriptan and compared the pharmacokinetics in men and women. The second study examined the doseproportionality in pharmacokinetics after fasting doses of 2.5, 5 and 10 mg, and the effect of food on a 5 mg dose. Blood pressure, heart rate, ECG, clinical chemistry, haematology and adverse events were also monitored. Results The mean (s.d.) absolute oral bioavailability was 0.41 (0.14 and 0.40) 0.09 after 2.5 mg and 0.48±0.14 and 0.36±0.07 after 5 mg in women and men, respectively. Without adjustment for bodyweight, plasma concentrations of zolmitriptan, but not 183C91, were higher in women than men. Mean (±s.d.) AUC was 32.7±10.1 and 60.2±26.8 ng ml −1 h after 5 mg in men and women, respectively (95% CI for ratio 0.43-0.77). After 2.5 mg mean (±s.d.) AUC was 18.4±5.4 and 23.1±9.9 ng ml −1 h in men and women, respectively (95% CI for ratio 0.61-1.09).
Introduction described [9] . The absolute bioavailability of a single 10 mg dose is 49% [10], compared with 14% reported for Zolmitriptan (Zomig, formerly 311C90) is a new 5-hydroxytryptamine (5-HT) 1B/1D receptor agonist [1] sumatriptan 100 mg [11] . Zolmitriptan is rapidly absorbed after oral administration but as plasma profiles show multiple developed for the acute oral treatment of migraine. Clinical studies have shown it to be effective and well tolerated in peaks in some subjects, individual t max values may vary from 0.5 to 5 h [6] . Zolmitriptan is eliminated mainly by the acute treatment of migraine at doses of 2.5-25 mg, with a headache response at 2 h in 62-81% of patients [2] [3] [4] , and metabolism followed by urinary excretion of the metabolites [9, 10] . There are three major metabolites; the active N-2.5 mg representing the optimal balance between efficacy and adverse effects [5, 6] . Zolmitriptan inhibits the peripheral desmethyl metabolite, 183C91, which is an agonist at 5-HT 1B/1D receptors with at least twice the potency of trigeminovascular system and is able to access central sites in the brainstem involved in processing cranial pain [7, 8] .
zolmitriptan, and the N-oxide and indole-acetic acid metabolites, both of which are pharmacologically inactive. The pharmacokinetics of single oral doses of zolmitriptan
The half-lives of zolmitriptan and its metabolites are similar at 2.5-3 h. After a single 10 mg oral dose, plasma men [10] , probably due to lower body weight, lower firstand two intravenous (i.v.) doses which were predicted, based on existing data, to give AUC values similar to those pass metabolism and lower systemic clearance.
In the previously reported studies [9, 10, 12] , assays of after oral 2.5 and 5 mg doses. It had been observed previously that zolmitriptan bioavailability was higher in zolmitriptan and its three major metabolites were performed using high performance liquid chromatography with fluowomen than men after an oral dose of 10 mg [10] so the i.v. doses were calculated using bioavailability estimates of rescence detection with a limit of quantification in plasma of 2 ng ml −1 [12] . This method was insufficiently sensitive 37% in men and 59% in women. Hence, women received i.v. doses of 1.475 and 2.95 mg and men received 0.925 and to enable full pharmacokinetic profiling of zolmitriptan at the optimal therapeutic dose of 2.5 mg. Therefore, 1.85 mg to correspond to 2.5 and 5 mg doses, respectively. The i.v. doses were given by infusion in a volume of 200 ml a more sensitive liquid chromatography-mass spectrometry (LCMS-MS) method was developed to assay zolmitriptan over 2 h via an IVAC 630-series infusion pump connected to a catheter placed in a suitable forearm vein. The oral and its active metabolite 183C91. In this paper we report the results of two studies using this assay method investigating doses were given after an overnight fast with 200 ml water.
There was a washout period of at least 5 days between doses. the pharmacokinetics, including bioavailability, of 2.5 and 5 mg oral doses of zolmitriptan, the dose-proportionality of 2.5, 5 and 10 mg doses and the effect of food on the Dose proportionality/food effect study pharmacokinetics of a 5 mg oral dose.
This was an open, randomized, balanced, four-period crossover study in six healthy men (mean (range) age 21 Clinical methods and procedures but excluding oral contraceptives), current or past history of drug abuse or excessive alcohol intake, hypertension Blood samples (5 ml) for assay of plasma concentrations of zolmitriptan and its active metabolite, 183C91, were (>150/90 mmHg ); clinical evidence of cardiovascular disease, Wolff-Parkinson-White syndrome or a family history collected predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 15 h after drug administration in the dose of premature (<55 years) cardiovascular disease. Female volunteers who were pregnant, breast feeding or not using proportionality/food effect study and at the same times but with the addition of a sample at 3.5 h post dose in the adequate contraception were excluded.
Ethical approval for both studies was obtained from the absolute bioavailability study. Blood was taken into lithium heparin tubes, centrifuged at 1500 g and 4°C for 10 min to Medical Ethics Committee of the Stichting Beoordeling Ethiek Bio-Medisch Onderzoek, Assen, The Netherlands, obtain plasma for assay of zolmitriptan and 183C91 which was then frozen at −20°C until analysis. and written informed consent was obtained from each volunteer.
Routine full blood counts and biochemistry evaluations were performed before and 24 h after each dose. Supine Volunteers were admitted to the research unit on the afternoon before each study day. Alcoholic beverages and systolic and diastolic blood pressures (SBP and DBP) and pulse rate were recorded 60 and 40 min before drug caffeine-containing foods and drinks were not allowed for 48 h before and during each study period and volunteers administration and at the same times as the blood samples until 10 h after each dose. Final readings were taken 24 h were also asked to refrain from strenuous exercise for 24 h prior to their arrival and during their stay at the research after administration. Patients were semirecumbent for the first 4 h and rested supine for 5 min prior to each BP unit. They rested on their beds for 4 h after each dose but thereafter were unrestricted except for 5 min rest prior to reading thereafter. A 12-lead ECG was recorded just before and 24 h after each drug administration. each blood pressure measurement.
Plasma concentrations and pharmacokinetics Absolute bioavailability study
This was an open, randomized, balanced, four-period Plasma concentrations of zolmitriptan and 183C91 were determined by automated solid phase extraction followed by crossover study in 10 healthy men (mean (range) age 23 (20-28 years) and weight 77.5 [65.1-90.2] (kg ) and 10 high performance liquid chromatography mass spectrometry. The solid phase extraction was carried out using 50 mg C18 healthy women (mean (range) age 23 (19-34 years) and weight 68.9 [52.0-85.0] (kg). Each volunteer received in Porvair Filtronics microlut blocks which were first conditioned using 0.5 ml aliquots of acetonitrile, water and 10 mm random order, single oral 2.5 and 5 mg doses of zolmitriptan ammonium formate buffer at pH 5. 0.1 ml of a 10 ng ml −1 the bioavailability of the 2.5 mg oral dose and that from the higher i.v. dose for the 5 mg oral dose. solution of internal standard ( 2 H 6 -zolmitriptan) and 0.4 ml 10 mm ammonium formate buffer were mixed with 0.5 ml aliquots of the plasma samples, which were then transferred to Statistical analysis the wells of the microlut blocks. After adsorption of the compounds onto the C18 matrix, the wells were washed with Absolute bioavailability study All pharmacokinetic parameters 0.5 ml aliquots of 10 mm ammonium formate buffer, water (except t max ) were log-transformed and subjected to analysis and acetonitrile. Zolmitriptan, 183C91 and internal standard of variance (anova). A mixed model was used, with factors were eluted from the matrix using 0.3 ml of 50% (v/v) of subject, sex, dose, period, formulation and interactions. acetonitrile, in 150 mm ammonium formate buffer. An aliquot Bioavailability was estimated for each oral dose with 95% of the elutant was injected onto a cation exchange chromatograconfidence intervals (CI) for all subjects and for each gender phy column (SpherisorbA SCX 5 mm, 30 (4.6 mm) and the separately. Pharmacokinetic parameters for zolmitriptan and separation was monitored using tandem mass spectrometry 183C91 were compared between men and women using (SciexA API-III mass spectrometer) with positive ion atmosanova and the differences between the genders with 95% pheric pressure ionization, using a turbo ionspray interface and CI were calculated. C max and AUC after intravenous multiple reaction monitoring.
zolmitriptan were dose-normalized for the between-gender The peak areas for zolmitriptan and 183C91 relative to comparison. For analyses conducted on a logarithmic scale, internal standard were calculated and the concentrations of point estimates and differences between treatments rethe analytes were determined by reference to the relevant sulted in geometric means and ratio estimates when backlinear calibration curves which were constructed by adding transformed. t max was summarized by descriptive statistics known amounts of zolmitriptan and 183C91 to control only. plasma and extracting these standards alongside each batch of samples analysed.
Dose proportionality/food effect study In order to determine The upper and lower limits of quantification were dose-proportionality, AUC and C max were dose-normalized 0.1 ng ml −1 and 15 ng ml −1 for both zolmitriptan and to a 5 mg dose before analysis. AUC(0,2), C max , t D and 183C91 in plasma. Quality control samples at three V /F were log-transformed and subjected to a 4-factor concentrations (0.3, 1.0 and 12 ng ml −1 ) were used. In the anova (factors of sex, subject, period and treatment). Point absolute bioavailability study, the accuracy (% bias) for estimates and 95% CI were calculated for the comparison of zolmitriptan and 183C91 ranged from −6.6 to −0.8% and AUC(0,2), C max , t D , and V /F between 2.5 and 5 mg, −1.1 to −0.7%, respectively. The overall precision (%CV) fasted, 10 mg and 5 mg, fasted and between 5 mg fed and for zolmitriptan and 183C91 ranged from 6.7 to 12% and 9.3 5 mg fasting. t max was analysed using the Wilcoxon signed to −14.3%, respectively. In the dose proportionality/food rank test, and differences between medians after 5 mg fed effect study, the accuracy ranged from -2.5-3.9% and −1.6 and 5 mg fasting were estimated with 95% CIs. to −15.4%, for zolmitriptan and 183C91, respectively. The Based on data from previous studies with zolmitriptan in overall precision (%CV) for zolmitriptan and 183C91 ranged healthy volunteer it was estimated 12 subjects would give from 5.5 to 12.5% and 7.2-11.4%, respectively. 80% power to detect a 30% change in AUC within a In both studies, noncompartmental pharmacokinetic parstudy group. ameters were calculated for each set of assay data using PC-SAS version 6.10. For both zolmitriptan and 183C91, the area under the plasma concentration-time curve (AUC) Results was determined using the trapezoidal rule and extrapolated All subjects completed the study as planned. beyond the last measurable concentration (Ct) to infinity (AUC(0,2) using the elimination rate constant (l z ). l z was obtained by log-linear regression of the terminal portion of Zolmitriptan pharmacokinetics the plasma concentration vs time curve, and the terminal plasma elimination half-life (t D ) was calculated as ln [2]/l z . After intravenous administration, peak zolmitriptan concentrations occurred at or near the end of the infusion followed Peak plasma concentration (C max ) and time to reach C max (t max ) were taken directly from the curves of plasma by a biphasic distribution and elimination phase (Figure 1 ). In contrast, after oral administration there was a fairly rapid concentration vs time. Clearance (CL) and the volume of distribution (V ) of zolmitriptan after intravenous adminisinitial absorption of drug, on average reaching 75-80% of eventual C max within 1 h; plasma concentrations were then tration were calculated as Dose/AUC(0,2) and CL/l z , respectively. CL and V after oral administration were sustained for up to 6 h with multiple peaks in some subjects, followed by the elimination phase. There was considerable calculated as for i.v. administration and expressed as CL/F and V /F in both studies, where F is bioavailability after an variability in zolmitriptan concentrations within each gender group. After oral doses of 2.5 and 5 mg in women, AUC oral dose. The absolute oral bioavailability ( F ) was calculated as: ranged between 13 and 42 ng ml −1 h and 26-100 ng ml
h, respectively; in men at the same doses the ranges were 11-26 ng ml −1 h and 13-44 ng ml −1 h, respectively.
After oral dosing, zolmitriptan AUC and C max , were higher in women than men although this was only statistically significant after 5 mg (Table 1) . There was no The AUC from the lower i.v. dose was used to calculate gender difference in oral bioavailability after 2.5 mg but the in weight adjusted clearance. In general, elimination halflife was slightly shorter in men, but none of the differences bioavailability of the 5 mg dose was higher in women (Table 1) . After intravenous dosing, especially at the higher between men and women was statistically significant (Tables 1 and 2 ). dose, plasma zolmitriptan concentrations were again higher in women than men even after correction for the difference in
Half-life was slightly shorter after i.v. compared with oral administration. Combining data from all subjects and both doses (Table 2) . However, there were no gender differences dose levels, the ratio of oral/i.v. half-life was 109% (95% CI 101, 117%).
Plasma zolmitriptan concentrations were proportional to dose between 2.5 and 10 mg (Table 3) . After food there were reductions of 13 and 16% in mean zolmitriptan C max and AUC, respectively (Table 3) ; these changes were not statistically significant.
183C91 pharmacokinetics
183C91 plasma profiles were similar to those of zolmitriptan after oral and intravenous dosing. In contrast to zolmitriptan, there were no gender differences in the concentrations of the active metabolite 183C91 (Tables 1 and 2 ). Consequently, due to higher zolmitriptan concentrations in women, the ratio of the AUC of 183C91 to that of zolmitriptan was lower in women than in men.
Concentrations of 183C91 were proportional across zolmitriptan doses with no significant effect of food on the pharmacokinetics of 183C91 (Table 3) .
Tolerability
The most frequently reported adverse experiences (AEs) were headache, somnolence, tightness of the throat, neck, jaw or chest, nausea and asthenia. These were generally mild, had their onset shortly after dosing, particularly after the commencement of the intravenous infusion and were of short duration. AEs were similar in nature after intravenous and oral treatments. Women generally reported more AEs than men; there were 13, 5, 15 and 12 AEs reported by women after 2.5 mg oral, 5 mg oral and low and high intravenous doses, respectively, and 8, 7, 3 and 8 by men at the same doses. After oral doses, the frequency of AEs did appear to be dose-related. There were 14, 20, 24, and 27 reports after 2.5 mg, 5 mg fasted, 5 mg fed and 10 mg, respectively, of these 9, 16, 16 and 17, respectively, were considered drug-related. No severe or serious AEs occurred in either study.
Increases in mean BP of up to 6 mmHg were observed in both studies after dosing with zolmitriptan, but there were no obvious differences between the treatments and no clinically significant increases. There were no clinically significant, treatment-emergent ECG, clinical chemistry or full blood count abnormalities in either study.
Discussion
Plasma concentrations at 5 and 10 mg (2.5 mg had previously not been measured accurately due to the limited sensitivity of the analytical method) were similar to those observed in previous studies [9, 10, 12] . There was dose proportionality of AUC(0,2) and C max across the doses studied. This is in agreement with previous findings over the higher dose range of 6-50 mg [9] . There was no significant effect of food on zolmitriptan or 183C91 concentrations which is important given the unpredictable onset of migraine attacks and the need to take drug whenever an attack should occur.
The mean absolute oral bioavailability of zolmitriptan (0.39 after 2.5 mg and 0.40 after 5 mg ) is within the range already reported after a 10 mg dose [10] and compares Table 3 Geometric mean pharmacokinetic parameters of zolmitriptan and 183C91 with mean ratios (95% confidence intervals) for comparisons between doses and between fed and fasted doses (n=12). favourably with the 0.14 reported for 100 mg sumatriptan dose-related. In the absence of a placebo control the small blood pressure changes observed in these studies must be [11] . The relatively low bioavailability of sumatriptan is due predominantly to presystemic metabolism and incomplete interpreted with caution. Dose-related, but clinically insignificant, increases in BP have been reported previously after oral absorption [13] . Comparison of the plasma concentration profiles for zolmitriptan and 183C91 after oral and i.v.
administration of zolmitriptan to healthy volunteers in double-blind, placebo-controlled studies [12, 15] . administration (and the higher 183C91/zolmitriptan AUC ratio after oral dosing ) suggests that first-pass metabolism
In conclusion, 2.5 and 5 mg doses of zolmitriptan were well tolerated. Mean bioavailability was #40%. A gender also plays a part in determining the oral bioavailability of zolmitriptan. Incomplete absorption contributes to the oral difference was observed after 5 mg doses with higher bioavailability in women than men, but this is not of clinical bioavailability as about 20% of an oral dose of zolmitriptan is recovered in faeces, presumably representing unabsorbed relevance. Plasma concentrations were proportional to dose and there was no significant effect of food on the drug [10] . In contrast to i.v. administration, the occurrence of multiple peaks in the plasma profile after oral adminispharmacokinetics of zolmitriptan or its active metabolite. tration suggests that absorption may occur over a considerable length of the gastrointestinal tract or may reflect delayed or partial gastric emptying after administration of 5-HT 1B/D References agonists [14] . The single peak after i.v. administration 1 Martin GR. Inhibition of the trigemino-vascular system with suggests that enterohepatic recirculation does not occur. accepted 24 May 1998) 
